Philip Gregory

Chief scientific officer · 2seventy bio · company speakers →

Dr. Gregory is the chief scientific officer at 2seventy bio. Prior to his current position, Dr. Gregory served in the same role at Bluebird Bio for six years and in multiple leadership positions at Sangamo BioSciences for almost 15 years. At Bluebird, he was one of the early investigators in the now exploding field of genome editing, and a substantial fraction of his research interests lie in the basic science, discovery, development, and translation of genome editing technologies for clinical applications. At Sangamo, Dr. Gregory drove research that led to the company's leadership in developing therapeutics using both zinc finger nuclease editing technology and ZFP-based engineered transcription factors. His passion for genome editing is to solve the myriad of challenges, including the efficiency and precision of the genome engineering outcome, for both ex vivo and in vivo applications of this powerful technology.

Is this you? Claim this profile →